| Methods |
Randomised double blind cross‐over placebo controlled trial, no details are available of this process in the abstract. |
| Participants |
N and setting ‐ not possible to determine these from the abstract., but the setting was most likely to have been France. Participants were people with aphasic symptoms with pure subcortical extrathalamic lesions. People were only included if the improvement of their aphasic symptoms was less than 40% during a one month period of preinclusion. |
| Interventions |
Piribedil 100mg per day in two daily doses versus placebo, given for one four week treatment period and then for one four week control period without wash out at cross‐over.
'Usual speech therapy' was provided to all participants during preinclusion and essay periods. This therapy is not described in the report.
Piribebil is a dopamine D2 agonist. |
| Outcomes |
Participants were evaluated at the end of each treatment period. They were tested on 5 sub tests of the Boston Aphasia Examination (BDAE, Goodlass 1972), and on the Score Aphasiologique de la Saltpetriere (no reference to this test is available). |
| Notes |
An abstract is the only report available. The author has written for further details, but no reply has been received at the time of the completion of this review. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
